Morgan Stanley’s Rhythm Pharmaceuticals RYTM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $61.2M | Buy |
703,978
+52,576
| +8% | +$5.11M | ﹤0.01% | 1896 |
|
|
2025
Q4 | $69.7M | Buy |
651,402
+186,212
| +40% | +$19.8M | ﹤0.01% | 1762 |
|
|
2025
Q3 | $47M | Sell |
465,190
-59,290
| -11% | -$5.5M | ﹤0.01% | 2065 |
|
|
2025
Q2 | $33.1M | Buy |
524,480
+20,431
| +4% | +$1.25M | ﹤0.01% | 2303 |
|
|
2025
Q1 | $26.7M | Sell |
504,049
-56,038
| -10% | -$3.11M | ﹤0.01% | 2397 |
|
|
2024
Q4 | $31.4M | Buy |
560,087
+95,483
| +21% | +$5.27M | ﹤0.01% | 2292 |
|
|
2024
Q3 | $24.3M | Sell |
464,604
-11,047
| -2% | -$529K | ﹤0.01% | 2599 |
|
|
2024
Q2 | $19.5M | Buy |
475,651
+292,781
| +160% | +$11.7M | ﹤0.01% | 2698 |
|
|
2024
Q1 | $7.92M | Sell |
182,870
-280,442
| -61% | -$12.3M | ﹤0.01% | 3525 |
|
|
2023
Q4 | $21.3M | Buy |
463,312
+26,904
| +6% | +$849K | ﹤0.01% | 3278 |
|
|
2023
Q3 | $10M | Buy |
436,408
+333,227
| +323% | +$7.46M | ﹤0.01% | 3126 |
|
|
2023
Q2 | $1.7M | Sell |
103,181
-113,440
| -52% | -$2.05M | ﹤0.01% | 4519 |
|
|
2023
Q1 | $3.86M | Sell |
216,621
-27,064
| -11% | -$680K | ﹤0.01% | 3985 |
|
|
2022
Q4 | $7.1M | Buy |
243,685
+13,488
| +6% | +$347K | ﹤0.01% | 3420 |
|
|
2022
Q3 | $5.64M | Sell |
230,197
-200,550
| -47% | -$3.73M | ﹤0.01% | 3577 |
|
|
2022
Q2 | $1.79M | Buy |
430,747
+175,255
| +69% | +$959K | ﹤0.01% | 4618 |
|
|
2022
Q1 | $2.94M | Sell |
255,492
-12,871
| -5% | -$113K | ﹤0.01% | 4213 |
|
|
2021
Q4 | $2.68M | Buy |
268,363
+62,897
| +31% | +$707K | ﹤0.01% | 4339 |
|
|
2021
Q3 | $2.68M | Sell |
205,466
-241,140
| -54% | -$3.68M | ﹤0.01% | 4327 |
|
|
2021
Q2 | $8.74M | Buy |
446,606
+345,757
| +343% | +$7.18M | ﹤0.01% | 3141 |
|
|
2021
Q1 | $2.15M | Buy |
100,849
+50,643
| +101% | +$1.47M | ﹤0.01% | 4201 |
|
|
2020
Q4 | $1.49M | Buy |
50,206
+34,527
| +220% | +$878K | ﹤0.01% | 4400 |
|
|
2020
Q3 | $340K | Sell |
15,679
-8,872
| -36% | -$203K | ﹤0.01% | 4842 |
|
|
2020
Q2 | $548K | Buy |
24,551
+13,451
| +121% | +$262K | ﹤0.01% | 4551 |
|
|
2020
Q1 | $169K | Sell |
11,100
-47,774
| -81% | -$855K | ﹤0.01% | 4939 |
|
|
2019
Q4 | $1.35M | Buy |
58,874
+46,135
| +362% | +$1.02M | ﹤0.01% | 4319 |
|
|
2019
Q3 | $274K | Buy |
12,739
+10,888
| +588% | +$234K | ﹤0.01% | 4975 |
|
|
2019
Q2 | $40K | Sell |
1,851
-2,758
| -60% | -$69.7K | ﹤0.01% | 5701 |
|
|
2019
Q1 | $127K | Sell |
4,609
-21,005
| -82% | -$604K | ﹤0.01% | 5284 |
|
|
2018
Q4 | $689K | Sell |
25,614
-1,038
| -4% | -$28.7K | ﹤0.01% | 4581 |
|
|
2018
Q3 | $777K | Sell |
26,652
-2,994
| -10% | -$94.6K | ﹤0.01% | 4714 |
|
|
2018
Q2 | $927K | Buy |
29,646
+12,866
| +77% | +$352K | ﹤0.01% | 4678 |
|
|
2018
Q1 | $334K | Sell |
16,780
-9,867
| -37% | -$262K | ﹤0.01% | 5226 |
|
|
2017
Q4 | $775K | Buy |
+26,647
| New | +$705K | ﹤0.01% | 4718 |
|
Other funds holding RYTM
RCM
BBA
VPM
VCM
PA
Morgan Stanley's RYTM Position: Q1 2026 in Review
Morgan Stanley increased its Rhythm Pharmaceuticals (RYTM) stake by 8.1% in Q1 2026, buying an estimated $5.11M and bringing the position to 703,978 shares worth $61.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1896.
Morgan Stanley first reported a position in RYTM in Q4 2017 and has held it in 34 quarters since. The position peaked at $69.7M in Q4 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.
- Morgan Stanley held 703,978 shares of Rhythm Pharmaceuticals worth $61.2M as of Q1 2026.
- Morgan Stanley bought 52,576 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $5.11M.
- Rhythm Pharmaceuticals made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #1896 holding.
- Morgan Stanley first reported a position in Rhythm Pharmaceuticals in Q4 2017 and has held it in 34 quarters since.
- Morgan Stanley's Rhythm Pharmaceuticals position peaked at $69.7M in Q4 2025.
- 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.